Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
NSPR - InspireMD Inc.
Market Cap 69.09M P/E - EPS this Y - Ern Qtrly Grth -
Income -25.52M Forward P/E -4.02 EPS next Y 13.40% 50D Avg Chg 34.00%
Sales 6.57M PEG - EPS past 5Y - 200D Avg Chg 120.00%
Dividend N/A Price/Book 2.02 EPS next 5Y - 52W High Chg -13.00%
Recommedations 2.00 Quick Ratio 7.02 Shares Outstanding 25.71M 52W Low Chg 302.00%
Insider Own 17.07% ROA -31.02% Shares Float 10.19M Beta 0.92
Inst Own 46.49% ROE -54.55% Shares Shorted/Prior 43.20K/47.23K Price 3.26
Gross Margin 23.85% Profit Margin - Avg. Volume 135,304 Target Price 4.50
Oper. Margin -474.99% Earnings Date Nov 4 Volume 30,952 Change -2.40%
Healthcare | Medical Devices | Israel
About InspireMD Inc.

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

InspireMD Inc. News
12/12/24 InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025
12/09/24 InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)
11/25/24 InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors
11/14/24 InspireMD Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023)
11/13/24 InspireMD Inc (NSPR) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Costs and ...
11/12/24 InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update
11/08/24 InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/04/24 InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th
10/21/24 One InspireMD Insider Raised Stake By 13% In Previous Year
10/15/24 InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System
10/08/24 InspireMD Advances with FDA Study Approval and Global Goals
10/07/24 InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System
09/16/24 InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System
09/14/24 Investors in InspireMD (NASDAQ:NSPR) have unfortunately lost 88% over the last five years
08/07/24 Companies Like InspireMD (NASDAQ:NSPR) Are In A Position To Invest In Growth
08/06/24 InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update
08/05/24 InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment
07/30/24 InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th
07/01/24 InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million
05/28/24 InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
ROUBIN GARY S Director Director Aug 18 Buy 1.909 35,500 67,770 164,194 08/22/22
Stuka Paul Director Director Nov 29 Buy 3.55 21,549 76,499 61,497 11/30/21
Stuka Paul Director Director Nov 22 Buy 3.54 20,392 72,188 20,420 11/23/21